Based on this rationale, Bonvini et al. tested the dual ALK-MET inhibitor crizotinib—a small-molecule tyrosine kinase inhibitor originally developed for cMET and approved for EML4-ALK-positive non-small-cell lung cancer (NSCLC)—as a potential therapeutic agent for RMS [308]. This evidence concerns the gene MET and non-small cell lung carcinoma.